Medicinal Chemistry Core for Antibiotic Drug Discovery
Official title: Medicinal Chemistry Core
Funded at Hackensack University Medical Center · NIH-11372878 · Data updated 2026-11-12
A dedicated Medicinal Chemistry Core will support antibiotic drug discovery by providing synthetic chemistry, computer-aided design, and structure-based optimization to help develop new treatments for resistant bacteria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | June 20, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,110,479 |
| NIH project number | 5U19AI189168-02 |
| Project ID | NIH-11372878 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with drug-resistant bacterial infections or populations impacted by rising resistant infections, who could benefit from new antibiotic therapies in the future.
✕Less likely to help
This core is a foundational research resource; directly benefiting patients depends on subsequent development and clinical testing of specific drugs.
What this research studies
If you have a bacterial infection or are at risk of one, this grant helps researchers design and optimize new small-molecule antibiotics. The core brings together chemistry experts and computational tools to create and test drug candidates that can fight difficult infections, including drug-resistant strains. It focuses on translating lab findings into lead compounds with the right properties for potential use in patients, working closely with existing project teams. The effort aims to accelerate the path from molecule idea to a promising therapeutic lead, with a strong track record in turning designs into real candidates.
Why it matters
Potential benefit: If successful, patients could benefit from new antibiotic options against resistant bacteria.
How similar studies have gone: Previous projects with medicinal chemistry optimization have yielded drug candidates, suggesting a promising path for these efforts.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Balkovec, James M — Hackensack University Medical Center
- Study coordinator: Balkovec, James M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.